Detection and confirmation of illicit drug use involving fentanyl
Chain of custody is required whenever the results of testing could be used in a court of law. Its purpose is to protect the rights of the individual contributing the specimen by demonstrating that it was under the control of personnel involved with testing the specimen at all times; this control implies that the opportunity for specimen tampering would be limited.
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
COCH | Chain of Custody Processing | No | Yes |
ADLTX | Adulterants Survey, CoC, U | Yes | Yes |
Adulterants testing will be performed on all chain of custody urine samples as per regulatory requirements.
Immunoassay/Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Fentanyl (Sublimaze)
Innovar
Sublimaze (Fentanyl)
Adulterants testing will be performed on all chain of custody urine samples as per regulatory requirements.
Urine
Container/Tube: Chain of Custody Kit (T282) containing the specimen containers, seals, and documentation required.
Specimen Volume: 5 mL
Collection Instructions: Collect random urine specimen in the container provided, seal, and submit with the associated documentation to satisfy the legal requirements for chain-of-custody testing.
Additional Information: Submitting less than 5 mL will compromise the ability to perform all necessary testing.
1. Chain of Custody Request is included in the Chain-of-Custody Kit (T282).
2. If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
2.1 mL
Gross hemolysis | OK |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 21 days |
Detection and confirmation of illicit drug use involving fentanyl
Chain of custody is required whenever the results of testing could be used in a court of law. Its purpose is to protect the rights of the individual contributing the specimen by demonstrating that it was under the control of personnel involved with testing the specimen at all times; this control implies that the opportunity for specimen tampering would be limited.
Adulterants testing will be performed on all chain of custody urine samples as per regulatory requirements.
Fentanyl is an extremely fast-acting synthetic opioid related to the phenylpiperidines.(1,2) It is available in injectable as well as transdermal formulations.(1) The analgesic effects of fentanyl are similar to those of morphine and other opioids(1): it interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissue.(1,3)
Fentanyl is approximately 80% to 85% protein bound. In plasma, the protein binding capacity of fentanyl decreases with increasing ionization of the drug. Alterations in pH may affect its distribution between plasma and the central nervous system (CNS). The average volume of distribution for fentanyl is 6 L/kg (range 3-8).(3,4)
In humans, the drug appears to be metabolized primarily by oxidative N-dealkylation to norfentanyl and other inactive metabolites that do not contribute materially to the observed activity of the drug. Within 72 hours of intravenous (IV) administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.(3,4)
The mean elimination half-life is(1-3):
-IV: 2 to 4 hours
-Iontophoretic transdermal system (Ionsys) terminal half-life: 16 hours
-Transdermal patch: 17 hours (13-22 hours; half-life is influenced by absorption rate)
-Transmucosal:
-Lozenge: 7 hours
-Buccal tablet
-100 mcg to 200 mcg: 3 to 4 hours
-400 mcg to 800 mcg: 11 to 12 hours
In clinical settings, fentanyl exerts its principal pharmacologic effects on the CNS. In addition to analgesia, alterations in mood (euphoria, dysphoria) and drowsiness commonly occur.(1,3) Because the biological effects of fentanyl are similar to those of heroin and other opioids, fentanyl has become a popular drug of abuse.
Chain of custody is a record of the disposition of a specimen to document each individual who collected, handled, and performed the analysis. When a specimen is submitted in this manner, analysis will be performed in such a way that it will withstand regular court scrutiny.
Negative
Cutoff concentrations:
Immunoassay screen
<2 ng/mL
Fentanyl by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
0.2 ng/mL
Norfentanyl by LC-MS/MS
1.0 ng/mL
The presence of fentanyl above 0.20 ng/mL or norfentanyl above 1.0 ng/mL is a strong indicator that the patient has used fentanyl.
Urine concentrations do not correlate well to serum drug levels. For therapeutic drug management, monitor serum levels.
Very high concentrations of butyl fentanyl (>5 mcg/mL) and acetyl fentanyl (>10 mcg/mL) can potentially interfere and cause a low positive (<0.5 ng/mL) fentanyl concentration, but no interference is noted with norfentanyl.
1. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG LL, Gilman AG, eds: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006:chap 21
2. Kerrigan S, Goldberger BA: Opioids. In: Levine ZB, ed. Principles of Forensic Toxicology. 2nd ed. AACC Press; 2003:187-205
3. DURAGESIC (fentanyl transdermal system). Package insert. Janssen Pharmaceutical Products. LP; 2006
4. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 8th ed. Biomedical Publications; 2008:616-619
5. Langman LJ, Bechtel LK, Meier BM, Holstege C. Clinical toxicology. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 7th ed. Elsevier; 2023
This screen is a homogeneous enzyme immunoassay technique. The immunoassay will be performed semiquantitatively. The immunoassay method is based on competition between free drug in the urine sample, and a drug labeled with the enzyme glucose-6-phosphate dehydrogenase for a fixed amount of specific antibody binding sites. Active enzyme converts nicotinamide adenine dinucleotide (NAD+) to NADH, which results in an absorbance change that can be measured spectrophotometrically at 340nm.(Package insert: Fentanyl Enzyme Immunoassay. Immunalysis Corporation; 10/2016)
The received urine sample is centrifuged, diluted, mixed with internal standard and ammonium hydroxide, and vortexed briefly. It is then extracted using supported liquid extraction, and the extract analyzed by an in-house developed liquid chromatography tandem mass spectrometry method.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
80354
G0480 (if appropriate)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FENTX | Fentanyl w/metabolite Conf, CoC, U | 67822-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
36190 | Norfentanyl by LC-MS/MS | 58383-1 |
36191 | Fentanyl by LC-MS/MS | 58381-5 |
36192 | Fentanyl Interpretation | 69050-3 |
36193 | Chain of Custody | 77202-0 |
36653 | Fentanyl Immunoassay Screen | 59673-4 |
Change Type | Effective Date |
---|---|
Test Status - Test Resumed | 2023-06-29 |
Test Status - Test Delay | 2023-06-26 |